SGS Leverages Phase Forward's InForm(TM) and Central Designer(TM) Solutions for Greater Clinical Trial Efficiencies
WALTHAM, Mass.--(BUSINESS WIRE)--
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, today
announced that SGS Life Science Services, a leading contract research
organization (CRO), has successfully developed multiple Phase I trials
across various therapeutic areas using Phase Forward's Central
Designer tool. The Central Designer technology provides one central
and independent environment for building studies, where all teams work
within a centralized system and one that allows for reuse of study
components. These Phase I trials were highly complex, involving more
than 1,500 forms in aggregate, and the teamwork between the two
organizations significantly improved the efficiency of the study
builds.
A Phase Forward customer since 2002, SGS is one of the largest EU
data management CROs, managing nearly 100 clinical trials and
processing one million case report form (CRF) pages each year.
"Our first priority is ensuring that our customers have access to
the best, most innovative technology for clinical trials," said Luc
Braeken, vice president, global clinical management, SGS. "Our many
years of experience with Phase Forward's InForm technology, and our
success with Central Designer, coupled with Phase Forward's premier
services team, has helped further position us in the Phase I space."
"Better trial management and drug development is highly dependent
on the technology being used, and CROs continue to play a critical
role in helping to reshape the efficiencies of EDC and related tools,"
said Mike Davies, vice president, global CRO partnerships, Phase
Forward. "Together, we help biopharmaceutical and medical device firms
realize the full benefits of these technologies across all trial
phases. We look forward to continued success with SGS in pursuit of
this goal."
About SGS Life Science Services
SGS Life Science Services, a Business unit of the SGS Group, has
30 years of experience as a global contract service organization
providing integrated solutions from preclinical activities to Phase I
through IV trials, bio-analytical and QC testing. With more than 1,300
employees and 2,000 clinical trials performed, SGS Life Science
Services serves the pharmaceutical, biotechnology and medical device
industries. SGS Life Science Services Biometrics group is one of the
largest EU Data Management CROs, processing over one million CRF pages
each year and offering comprehensive expertise, including in-depth
experience in EDC, CDISC and extensive high throughput capabilities.
The SGS Group is the global leader and innovator in inspection,
verification, testing and certification services. Founded in 1878, SGS
is recognized as the global benchmark in quality and integrity. With
more than 50,000 employees, SGS operates a network of more than 1,000
offices and laboratories around the world. Additional information
about SGS is available at www.sgs.com/CRO.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. The company offers
proven solutions for electronic data capture (InForm(TM)), phase I
clinic automation (LabPas(TM)), clinical data management
(Clintrial(TM)), clinical trials signal detection (CTSD(TM)),
strategic pharmacovigilance (Empirica Signal(TM)) and Signal
Management, adverse event reporting (Empirica Trace(TM)), applied data
standards (WebSDM(TM)) and Web-integrated interactive response
technologies (Clarix(TM)). In addition, the company provides services
in the areas of application implementation, hosting and validation,
data integration, business process optimization, safety data
management and industry standards. Phase Forward's products and
services have been utilized in over 10,000 clinical trials involving
more than 1,000,000 clinical trial study participants at over 280
organizations and regulatory agencies worldwide including:
AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli
Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard
Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk,
PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis,
Schering-Plough Research Institute, Servier, Tibotec and the U.K.
Medicines and Healthcare Products Regulatory Agency. Additional
information about Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to, among other things,
the performance and features of Phase Forward's products and services,
future business and operations plans of Phase Forward customers and
alliance partners, and the ability of Phase Forward's customers and
alliance partners to realize benefits from the use of Phase Forward's
products and services. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond Phase Forward's control, which could cause
actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties
include, among other things, the ability of Phase Forward's customers
and alliance partners to realize benefits from the use of its products
and services, changes in regulatory requirements applicable to Phase
Forward's customers and alliance partners, the manner in which Phase
Forward's customers and alliance partners conduct business and the
possibility that their needs or plans may change over time, and
competition. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or circumstances
or otherwise. For additional disclosure regarding these and other
risks faced by Phase Forward, see the disclosure contained in Phase
Forward's public filings with the Securities and Exchange Commission
including, without limitation, its most recent Annual Report on Form
10-K.
Source: Phase Forward
